Cost effectiveness analysis of immunotherapy regimens currently approved in advanced or recurrent endometrial cancer: An analysis of the NRG-GY 018, RUBY, and DUO-E trials

Recognizing existing differences in study design, both pembrolizumab and durvalumab may be more cost effective than dostarlimab in our model. This appears to largely be driven by differences in duration of maintenance therapy rather than differences in effectiveness or individual drug cost. Immunotherapy does not appear to be as cost effective in the pMMR population.

Authors

Institutions

Publication Details

Journal
Gynecologic Oncology Reports
Published
2026-02-18
DOI
https://doi.org/10.1016/j.gore.2026.102050
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cost effectiveness analysis of immunotherapy regimens currently approved in advanced or recurrent endometrial cancer: An analysis of the NRG-GY 018, RUBY, and DUO-E trials

Liang Su-ying, Alex Francoeur, Brittany File, DS Kapp et al.
Gynecologic Oncology Reports
Endometrial and Cervical Cancer Treatments
article

Cost effectiveness analysis of immunotherapy regimens currently approved in advanced or recurrent endometrial cancer: An analysis of the NRG-GY 018, RUBY, and DUO-E trials

Liang Su-ying, Alex Francoeur, Brittany File, DS Kapp, Eunji Choi, Max Brameld, Michael T. Richardson, Krishnansu S. Tewari, John K. Chan, Caitlin R. Johnson
article en

Abstract

Recognizing existing differences in study design, both pembrolizumab and durvalumab may be more cost effective than dostarlimab in our model. This appears to largely be driven by differences in duration of maintenance therapy rather than differences in effectiveness or individual drug cost. Immunotherapy does not appear to be as cost effective in the pMMR population.

Gynecologic Oncology ReportsVol. 64
Sutter Health (US), University of California, Los Angeles (US), University of California, Irvine (US), Cornell University (US), Weill Cornell Medicine (US), Stanford University (US)
Openalex Percentile: Top 48%
Endometrial and Cervical Cancer Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Cost effectiveness analysis of immunotherapy regimens currently approved in advanced or recurrent endometrial cancer: An analysis of the NRG-GY 018, RUBY, and DUO-E trials — Liang Su-ying, Alex Francoeur, et al. · Gynecologic Oncology Reports (2026) | TGRS Research Map | TGRS